Brokerage firm Piper Jaffray Maintains its rating on Shire PLC (ADR)(NASDAQ:SHPG). In a research note issued to the investors, the brokerage major Raises the price-target to $201.00 per share. The shares have been rated Neutral. The rating by Piper Jaffray was issued on Sep 30, 2016.
Shire PLC (ADR) (SHPG) shares turned negative on Tuesdays trading session with the shares closing down -0.85 points or -0.43% at a volume of 8,25,150. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $197.91. The peak price level was also seen at $197.91 while the days lowest was $194.08. Finally the shares closed at $194.59. The 52-week high of the shares is $231.32 while the 52-week low is $147.6. According to the latest information available, the market cap of the company is $58,390 M.
Shire PLC (ADR)(SHPG) last announced its earnings results on Aug 2, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $2.43B. Analysts had an estimated revenue of $1.94B. Earnings per share were $3.38. Analysts had estimated an EPS of $3.03.
Shire plc is a biopharmaceutical company. The Company along with its subsidiaries is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience Gastrointestinal (GI) Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate) ADDERALL XR (mixed salts of a single-entity amphetamine) INTUNIV (extended release guanfacine) EQUASYM (methylphenidate hydrochloride) modified release (XL) BUCCOLAM LIALDA (mesalamine)/ MEZAVANT(mesalazine) PENTASA (mesalamine) RESOLOR (prucalopride) REPLAGAL (agalsidase alfa) VPRIV (velaglucerase alfa) FIRAZYR (icatibant) CINRYZE C1 esterase inhibitor (human) FOSRENOL (lanthanum carbonate) XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).